Evolution and current status of the subclassification of intermediate hepatocellular carcinoma

Table 2 Studies validation and modification of Bolondi criteria

Patients (n)	Treatment	Median follow-up	Ref.	B1	B2	B3	B4	Independent risk factor of survival
80	LR, TACE	28.19 mo	Ciria et al[9]	OS rate: 43.75%; 5-yr survival rate (62.9%)	OS rate: 40%; 5-yr survival rate (28.1%)	OS rate: 11.25%; 5-yr survival rate (28.1%)	OS rate: 5%; 5-yr survival rate (15.1%)	Total bilirubin, subclassification stages B2 and B3-4 vs B1
90	TAE	NR	Scaffaro et al[10]	Mean OS: 33.6 mo	Mean OS: 28.6 mo	Mean OS: 19.0 mo	Mean OS: 13.0 mo	NR
580	TAE	NR	Wang et al[12]	Median OS: 28.8 mo; 1, 3, 5-yr survival rate: 80%, 39.5%, 21.4%	Median OS: 15.6 mo; 1, 3, 5-yr survival rate: 59.2%, 23%, 13.9%	Median OS: 6 mo; 1, 3, 5-yr survival rate: 39.5%, 11.2%, 7.4%	Median OS: 9.6 mo; 1, 3, 5-yr survival rate: 46.2%, 23.1%, 7.7%	AFP level, AST, and substage B2, B3, and B4 vs B1
254	TACE, LR, OLT	15.4 mo	Weinmann et al[13]	Median OS: 31.9 mo; 1, 2-yr survival rate: 82.93%, 60.98%	Median OS: 26.9 mo; 1,2-yr survival rate: 72.9%, 52.44%	Median OS: 13.5 mo; 1, 2-yr survival rate: 65%, 40%	Median OS: 10.9 mo; 1, 2-yr survival rate: 48.98%, 38.35%	Total bilirubin, MELD score, presence of ascites, and the therapies resection and OLT.
269	NR	NR	Giannini et al[11]	Median OS: 25 mo	Median OS: 16 mo	Median OS: 9 mo	Median OS: 5 mo	Subclassification of BCLC B, MELD score, and platelet count.
821	TACE	NR	Kim et al[14]	1, 3, 5-yr survival rate: 95.1%, 66.4%, 41.2%	1, 3, 5-yr survival rate: 78.4%, 33%, 20.3%	1, 3, 5-yr survival rate: 59.3%, 10.5%, 0	1, 3, 5-yr survival rate: 57.4%, 43.7%, 17%	NR

LR: Liver resection; OS: Overall survival; TACE: Transcatheter arterial chemoembolization; OLT: Orthotopic liver transplantation; MELD: Model of end-stage liver disease; NR: Not reported.